Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05918523 · ClinicalTrials.gov registry record
A Long-Term Follow-Up Study of Participants Exposed to REACT
A clinical trial of Chronic Kidney Diseases and Diabetic Kidney Disease, sponsored by Prokidney.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT05918523 is a study of Chronic Kidney Diseases and Diabetic Kidney Disease that is actively recruiting participants, run by Prokidney. The registered enrollment target is 80 participants, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05918523, a study of Chronic Kidney Diseases and Diabetic Kidney Disease, is actively recruiting participants, sponsored by Prokidney.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
Conditions Studied
Interventions
- BIOLOGICAL Renal Autologous Cell Therapy (REACT)
Study Locations (1)
Idaho
- Boise Kidney & Hypertension Institute - Meridian
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2023-12-11 |
| Est. Completion | 2028-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05918523
The ClinicalTrials.gov registry entry for NCT05918523 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 444-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (82% lower). The listed sponsor is Prokidney, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which Renal Autologous Cell Therapy (REACT) is the first listed.
NCT05918523 reports 1 study location spanning 1 distinct geographic area - top geographies include Idaho.
Frequently Asked Questions
What is clinical trial NCT05918523 about?
NCT05918523 is a clinical study titled "A Long-Term Follow-Up Study of Participants Exposed to REACT". The purpose of this study is to evaluate the long-term safety of up to two gelatin-hydrogel formulation REACT injections given 3 to 6 months apart and delivered percutaneously into same kidney on renal function in participants with chronic kidney disease (CKD).
What is the current status of trial NCT05918523?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2023-12-11. Estimated completion is 2028-03.
What conditions does trial NCT05918523 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases, Diabetic Kidney Disease.
What interventions are being tested in trial NCT05918523?
The interventions under investigation include: Renal Autologous Cell Therapy (REACT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05918523?
This trial is sponsored by Prokidney, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05918523 being conducted?
This trial has 1 study location across Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
RECRUITING
-
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Mindfulness in Chronic Kidney Disease
RECRUITING · NA
-
Ferric Citrate and Chronic Kidney Disease in Children
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.